Steady growth throughout the year propelled imaging software developer Median Technologies to a double-digit gain in revenue in 2019.
The company advanced revenue by 41% to 9 million euros, compared with 6.5 million euros in 2018. After a variety of expenses, the company posted a net loss of 8 million euros in fiscal 2019, compared with a net result loss of 15.3 million euros the year before.
Among the expenditures in 2019 were 4.7 million euros for research and development, with much of that spending going toward the company's iBiopsy artificial intelligence image processing software, which is designed to use biomarkers to identify specific signatures of certain diseases for their early detection, quantify disease severity, and monitor the efficacy of treatment.
